GNTbm
華上生技醫藥股份有限公司
GNTbm is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is GNTbm-38 (Phase 1; not yet recruiting, Solid Tumor (Phase I); Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| GNTbm-38 | — | Phase 1; not yet recruiting | Solid Tumor (Phase I); Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | — | 2026-09-25 | Trial registry |
| GNTbm-TKI / Cbo-23 | — | Preclinical GLP pharmacology and toxicology studies | Solid tumors; neuroendocrine tumors (planned) | — | — | Company disclosure |
| Tucidinostat / KEPIDA | — | Phase 3 KEPIDA-4 trial will not proceed | Advanced colorectal cancer | Taiwan | 2025-05-02 | Company disclosure |
Key events
- KEPIDA and GNTbm-38 research presented at a scientific meeting (company disclosure)